Cook G J, Houston S, Barrington S F, Fogelman I
Clinical PET Center and Department of Oncology, Guys Hospital, United Medical and Dental Schools, London, United Kingdom.
J Nucl Med. 1998 Jan;39(1):99-103.
Technetium-99m HL91 is a potential agent for imaging hypoxic tissue in vivo. A pilot evaluation using a prototype formulation assessed efficacy in tumor imaging and compared results with 18F-fluorodeoxyglucose (FDG) PET.
Ten patients with malignant tumors were included. Tumors included carcinoma of the bronchus (n = 3), carcinoma of the thyroid (n = 2), lymphoma (n = 2), soft tissue sarcoma (n = 1), carcinoid (n = 1) and carcinoma of the breast (n = 1). Whole-body planar scans and localized SPECT scans were performed at 1 and 4 hr postinjection of 600 MBq 99mTc HL91. Half-body and localized emission/transmission 18F-FDG PET scans were performed 60 min postinjection 370 MBq 18F-FDG in eight patients. Lesion-to-normal tissue background ratios were measured for all 99mTc HL91 and 18F-FDG PET scans and percentage uptake and standardized uptake values measured for 99mTc HL91 and 18F-FDG PET, respectively.
Technetium-99m HL91 showed visible uptake into the tumor area in all seven studies where the tumor was clearly identified by 18F-FDG PET; 99mTc HL91 uptake was not detected in one study (carcinoid) in which 18F-FDG was weakly positive. Two further tumors, in which PET correlation was not available, showed accumulation of 99mTc HL91. In two 99mTc HL91 studies, abnormality was apparent only on SPECT images. Lesion-to-normal tissue background ratios for 99mTc HL91 ranged from 1.22/2.53 at 1 hr and 1.33/2.89 at 4 hr on planar images and 1.23/5.2 and 1.67/14.6 on SPECT images, respectively.
In this study, the use of 99mTc HL91 resulted in uptake in the majority of malignant tumors identified by 18F-FDG-PET. Technetium-99m HL91 exhibits good imaging characteristics, with imaging at 4 hr providing good lesion-to-normal tissue background ratios, that are further enhanced by SPECT.
锝-99m HL91是一种用于体内缺氧组织成像的潜在试剂。一项使用原型制剂的初步评估评估了其在肿瘤成像中的疗效，并将结果与18F-氟脱氧葡萄糖（FDG）PET进行了比较。
纳入10例恶性肿瘤患者。肿瘤包括支气管癌（n = 3）、甲状腺癌（n = 2）、淋巴瘤（n = 2）、软组织肉瘤（n = 1）、类癌（n = 1）和乳腺癌（n = 1）。注射600 MBq 99mTc HL91后1小时和4小时进行全身平面扫描和局部SPECT扫描。8例患者在注射370 MBq 18F-FDG后60分钟进行半身和局部发射/透射18F-FDG PET扫描。测量所有99mTc HL91和18F-FDG PET扫描的病变与正常组织背景比值，并分别测量99mTc HL91和18F-FDG PET的摄取百分比和标准化摄取值。
在所有7项通过18F-FDG PET清楚识别肿瘤的研究中，锝-99m HL91均显示在肿瘤区域有明显摄取；在一项18F-FDG弱阳性的类癌研究中未检测到99mTc HL91摄取。另外两个无法进行PET相关性分析的肿瘤显示有99mTc HL91聚集。在两项99mTc HL91研究中，异常仅在SPECT图像上明显。平面图像上99mTc HL91的病变与正常组织背景比值在1小时时为1.22/2.53，4小时时为1.33/2.89，SPECT图像上分别为1.23/5.2和1.67/14.6。
在本研究中，使用99mTc HL91导致在大多数通过18F-FDG-PET识别的恶性肿瘤中有摄取。锝-99m HL91具有良好的成像特性，4小时成像时病变与正常组织背景比值良好，SPECT可进一步增强该比值。
